ALTASCIENCES
23.2.2021 17:54:13 CET | Business Wire | Press release
Altasciences is pleased to have contributed to the recent FDA approval of Vibegron, by performing three early phase clinical trials. Vibegron is a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. The approval was announced by Urovant Sciences on December 23, 2020.
“We take tremendous pride in contributing to the FDA approval of much-needed medicines that improve the health and wellbeing of patients,” said Amy Denvir, General Manager at Altasciences’ Kansas clinical pharmacology unit. “Working with Urovant Sciences on this program has been a pleasure, and we are delighted to see it come to fruition. ”
Altasciences’ expert clinical teams provided clinical support for two drug-drug interaction studies and a bioavailability trial, conducted in 2018 and 2019, in healthy subjects. These trials were supported by Altasciences’ data services team, who performed the full data management and reporting for the associated clinical studies.
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005896/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compvide Announces Commercial Launch of CIMED and Presents New Research at European Meeting on Complement in Human Disease (EMCHD) 202621.10.2026 12:47:00 CEST | Press release
Compvide, Inc. today announced the commercial launch of its CIMED platform. The CIMED-AP, CIMED-LP, and CIMED-CP kits assess the alternative, lectin, and classical complement pathways, respectively, using 50% serum to support testing under more physiological conditions. The commercial launch follows Compvide’s participation in the 20th European Meeting on Complement in Human Disease (EMCHD), held September 1–5, 2026, in Cardiff, Wales. Through a scientific presentation, poster, and exhibition, the company shared research highlighting the importance of assay conditions in evaluating complement activity and the effects of complement-targeting therapies. Unlike conventional assays that often use highly diluted serum, CIMED assays use 50% serum. Research presented by Compvide at EMCHD highlighted how serum dilution can influence measurements of complement inhibition, particularly at lower drug concentrations. These findings underscore the importance of assay conditions when evaluating pote
Forrester’s 2027 Technology And Security Predictions: AI Will Account For 20% Of All Business Technology Spend21.10.2026 10:30:00 CEST | Press release
Technology and security leaders will face mounting pressure to control AI costs, justify infrastructure choices, and manage emerging risks without slowing innovation According to Forrester’s (Nasdaq: FORR) 2027 technology and security predictions, CIOs and CISOs will face growing pressure to realize returns on their AI investments in infrastructure, security, digital sovereignty, and emerging technologies. Additionally, with global technology spending forecasted to reach $6.1 trillion in 2027, technology leaders will need to balance AI governance and control with innovation and business agility. Forrester’s Predictions reports offer forward-looking insights into the trends and signals that empower leaders and their teams to think beyond the conventional and ignite bold ideas for the year ahead. Forrester’s technology and security predictions cover topics including AI, automation and robotics, tech leadership, cloud computing, tech infrastructure and operations, enterprise software, sof
Forrester’s 2027 B2C Marketing, CX, And Digital Predictions: Rising AI Costs Will Force B2C Leaders To Scale Back A Third Of AI Initiatives21.10.2026 10:30:00 CEST | Press release
According to Forrester’s (Nasdaq: FORR) 2027 B2C marketing, customer experience, and digital predictions, rising AI costs will force B2C marketing leaders to scale back a third of AI initiatives. As AI usage grows and martech vendors increasingly adopt usage-based pricing models, every agent interaction, generated asset, and automated workflow becomes a billable event. As a result, leaders will need to make tougher decisions and focus investments on AI initiatives that deliver measurable business value. Forrester’s Predictions reports deliver forward-looking insights into the signals and trends that will shape the year ahead. Forrester’s consumer marketing, CX, and digital business predictions cover topics including B2C marketing, customer experience, consumer behavior, digital commerce, media and advertising, marketing agencies, content and creative, and trust and privacy. Additional highlights from Forrester’s 2027 B2C marketing, CX, and digital predictions include:CX staffing will r
LTM Launches BlueVerse™ ValueMesh™ to Help Enterprises Scale AI Across Oracle Transformations21.10.2026 10:30:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ ValueMesh™, an AI execution fabric designed to help enterprises industrialize AI across the Oracle transformation lifecycle, from strategy and implementation to operations and continuous innovation. BlueVerse™ ValueMesh™ is developed and validated by LTM as part of its Cloud Services expertise. Built on LTM's deep Oracle expertise and BlueVerse™ portfolio, BlueVerse™ ValueMesh™is designed to help enterprises industrialize AI across their Oracle transformation journey. It brings together AI-native delivery, intelligent automation, AI agents, managed services, intelligent business processes, industry solutions, data, and governance in a unified execution model designed to help organizations move beyond fragmented initiatives and isolated pilots and pursue scalable innovation, continuous optimization, and measurable business outcomes across their Oracle estate. At its core, Bl
Forrester’s 2027 B2B Go-To-Market Predictions: AI Agents Will Influence 75% of B2B Purchase Decisions21.10.2026 10:30:00 CEST | Press release
To remain competitive, providers must strengthen customer trust, substantiate value claims, and offer human expertise and guidance According to Forrester’s (Nasdaq: FORR) 2027 B2B go-to-market predictions, business buyers will increasingly deploy AI agents to handle tasks across the buying process, from supplier discovery and information gathering to contract-renewal analysis. While truly autonomous buying will remain concentrated in high-volume, low-risk, and repeatable purchases, the ubiquity of these agents will require providers to ensure that their systems and sellers can respond with speed, accuracy, and consistency. Forrester’s B2B Predictions reports, covering topics including B2B go-to-market strategy, business buyers, and content and creative, offer forward-looking insights to help executives and their teams anticipate change, reduce uncertainty, and make confident decisions ahead of market shifts. Key highlights from the 2027 B2B go-to-market predictions include: Buyers will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom